Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2013 /
PETROC / OV21: Phase II/III trial of peritoneal treatment for ovarian cancer

3rd - 6th Nov 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.11.13
Views: 4061

Dr Chris Gallagher - Barts and the London NHS Trust, UK

Dr Chris Gallagher talks to ecancer at the 2013 NCRI Cancer Conference in Liverpool about the PETROC study.

The trial is a meta analysis of phase III trials of post operative intraperitoneal chemotherapy in epithelial ovarian cancer, fallopian tube and primary peritoneal cancer.

In the 853 patients that participated, with 6 years follow-up, there was a reduction of 16% in risk of progression, 17% in risk of death, and increased median progression free (20 to 25 months),and overall (51 to 62 months )survival.

PETROC/OV21 is designed to investigate women not able to be optimally debulked at primary surgery who have had primary IV chemotherapy and optimal interval debulking followed by IVor IP treatment, with dose paclitaxel plus carboplatinor cisplatin.

The study reached the conclusion that intraperitoneal chemotherapy after interval debulking surgery is feasible and safe.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation